Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine

作者：Hao Chen, Yang Weng, Donghan Zheng, Tian Li, Nan Xu, Longdan Kang, Liang Feng · 发表于：Journal of Advanced Research · 年份：2025 · DOI：10.1016/j.jare.2025.10.026 · 被引用次数：3 · 研究领域：Renal cell carcinoma treatment、Cancer Genomics and Diagnostics、Bladder and Urothelial Cancer Treatments

The heterogeneity of urinary system tumors and its impact on precision medicine. The diagram highlights genetic mutations, molecular phenotype differences, and immune microenvironment variability in bladder cancer, kidney cancer, and prostate cancer. These findings emphasize how these heterogeneities affect treatment responses and the role of genomic profiling in targeted therapies for personalized treatment • Precision medicine has potential for the treatment of urinary system tumors. • Urinary system tumors are characterized by molecular and genetic heterogeneity. • Targeted therapy represents a more precise and individualized therapeutic strategy. • EGFR and VEGF are prominent molecular targets for the treatment of urinary system tumors. Urinary system tumors, including bladder, kidney, and prostate cancers, impose a substantial health burden worldwide and exhibit significant molecular and genetic heterogeneity. of Review : This review delves into the intricate landscape of targeted therapy for urinary system tumors and its pivotal role in advancing precision medicine. Key Scientific Concepts of Review : Urinary system tumors include kidney cancer, bladder cancer, and prostate cancer. They exhibit remarkable heterogeneity at the molecular level, which challenges the effectiveness of conventional treatments. Compared with conventional therapy, precision medicine is a tailored approach that customizes treatments for individual patients on the basis of their unique genetic, m...